Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab Phase I in Healthy Volunteers
NCT04369586Phase 1Completed
- Sponsor
- Xijing Hospital
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of meplazumab in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Xijing Hospital. Primary endpoint: Incidence rate of treatment-related adverse events at 28 days. Started Apr 2020; status: completed.
02
Drugs
meplazumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04369586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369586.